Company: PTPI
Filing Date: 2025-03-14
Form Type: PRER14A
Source: 0001104659-25-024012
Chunk: 11

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-03-14
Form: PRER14A
Chunk 11
---
 entitled to vote at the Special Meeting.
On the Record Date, there were 29,929,668 shares of our Common Stock issued and outstanding and entitled to vote at the Special Meeting
and 567.85 shares of Series A Preferred Stock issued and outstanding and entitled to vote at the Special Meeting, and, pursuant to
the terms of the Series A Preferred Stock as set forth in the Certificate of Designations for the Series A Preferred Stock (as
amended, the “Certificate of Designations”), the holders of the Series A Preferred Stock are entitled to an aggregate
of 252,374 votes on the proposals described in this Proxy Statement.

Purchasers of shares of Common
Stock and/or pre-funded warrants (the “Pre-Funded Warrants”) exercisable for shares of Common Stock sold in the Offering are
not entitled to vote such shares of Common Stock or shares of Common Stock issuable upon exercise of such Pre-Funded Warrants on the Issuance
Proposal.

You do not need to attend
the Special Meeting to vote your shares. Shares represented by valid proxies, received in time for the Special Meeting and not revoked
prior to the Special Meeting, will be voted at the Special Meeting. For instructions on how to change or revoke your proxy, see “May I
Change or Revoke My Proxy?” below.

How Many Votes Do I Have?

Each share of our Common
Stock that you own entitles you to one vote. Pursuant to the terms of the Series A Preferred Stock as set forth in the Certificate
of Designations for the Series A Preferred Stock, the holders of Series A Preferred Stock are entitled to approximately 252,374
votes on the proposals described in this Proxy Statement. There is no cumulative voting.

What is the Purpose of the Special Meeting?

At the Special Meeting, stockholders will consider
and vote upon the following matters:

Proposal 1 (the “Issuance Proposal”):

To approve, for purposes
of complying with Nasdaq Listing Rule 5635(d), the issuance of shares of our Common Stock underlying the Series A warrants (the “Series
A Warrants”) and Series B warrants (the “Series B Warrants” and, together with the Series A Warrants, the “Series
Warrants”), including by operation of certain anti-dilution provisions contained therein, issued by us in a public offering transaction
(the “Offering”) on February 19, 2025 (including an aggregate of approximately 1,064,846,416.